{
  "guideline": {
    "id": "PA166104827",
    "name": "Annotation of FDA Label for atomoxetine and CYP2D6",
    "source": "FDA",
    "version": 30,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104827",
    "relatedChemicals": [
      {
        "id": "PA134688071",
        "name": "atomoxetine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312152",
      "name": "Recommendation Annotation PA166312152",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216391,
        "html": "<p>&quot;In patients who are known to be CYP2D6 PMs, STRATTERA [atomoxetine] should be initiated at 0.5 mg/kg/day and only increased to the usual target dose of 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Strattera (Atomoxetine hydrochloride), NDA021411, Eli Lilly and Company",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021411"
    }
  ],
  "version": "2024-02-29-20-19"
}